| Lupin gains on Q2 net rise | 27-OCT-09 |
|
| The stock extended gains and touched a high of Rs 1,275 - up 4.5% from the day's low. The stock finally settled with a 1% gain at Rs 1,251. Over 42,372 shares were traded on the BSE today. |
|
|
|
| Lupin: Steady growth | 27-OCT-09 |
|
| Lupin turned in good numbers this quarter across geographies, slightly above analyst expectations. |
|
|
|
| Lupin Q2 net up 39% at Rs 160 cr | 27-OCT-09 |
|
| Improved sales in key global markets saw a 39 per cent spurt in the net profit of pharma major Lupin Ltd during the quarter. |
|
|
|
| Lupin Q2 net up 39% at Rs 160.3 crore | 26-OCT-09 |
|
| Pharmaceutical firm Lupin Ltd reported 39 per cent increase in its net profit for the second quarter ended September at Rs 160.3 crore on the back of robust sales across all markets. |
|
|
|
| Lupin slips despite huge growth in sales | 22-OCT-09 |
|
| The scrip slipped to a low of 1,186 and finally ended at Rs 1,199, down 4% from the previous close. The counter clocked volumes of 22,837 shares on the BSE today. |
|
|
|
| Lupin sales growth leaps over volume growth | 22-OCT-09 |
|
| Lupin— the largest manufacturer of anti-TB drugs in the world — has recorded one of the sharpest rise in sales in the domestic market over the last 12 months, according to the latest data available from research firm ORG-IMS. |
|
|
|
|
|
|
| Lupin pills hit legal wall in United States | 11-OCT-09 |
|
| Teva Women's Health of Israel and Warner Chilcott of Puerto Rico have sued India’s Lupin in separate patent infringement cases in the US. This is being seen as an attempt to block the Indian company’s plans to tap the $3.3 billion (Rs 13,860 crore) oral contraceptive market in the US. |
|
|
|
| Lupin up 4% on unique Indian deal | 06-OCT-09 |
|
| The stock extended gains and touched a high of Rs 1,239. It finally ended with a gain of 3.5% at Rs 1,212. Over 77,090 shares changed hands at the counter today. |
|
|
|
| Lupin out-licenses drug to US major Salix | 06-OCT-09 |
|
| Pharma major Lupin Ltd has out-licensed a new drug delivery system, developed in-house, to US-based drug major Salix Pharmaceuticals. This is the first such deal done by an Indian company. |
|
|
|
| Analysts' corner | 05-OCT-09 |
|
| After months of negotiations, the potential merger between Bharti Airtel and MTN has been called off. This comes on the back of South African government's denial in accepting the deal structure proposed by Bharti and MTN. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Content Guide
